참고문헌
- Avila MA, Berasain C, Sangro B, Prieto J (2006). New therapies for hepatocellular carcinoma. Oncogene, 25, 3866-84. https://doi.org/10.1038/sj.onc.1209550
- Berk V, Kaplan MA, Tonyali O, et al (2013). Efficiency and side effects of sorafenib therapy for advanced hepatocellular carcinoma: a retrospective study by the anatolian society of medical oncology. Asian Pac J Cancer Prev, 14, 7367-9. https://doi.org/10.7314/APJCP.2013.14.12.7367
- Bruix J, Sherman M (2011a). Management of hepatocellular carcinoma: an update. Hepatology, 53, 1020-2. https://doi.org/10.1002/hep.24199
- Bruix J, Sherman M (2011b). Management of hepatocellular carcinoma: an update. Hepatology, 53, 1020-2. https://doi.org/10.1002/hep.24199
- Carlomagno F, Anaganti S, Guida T, et al (2006). BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst, 98, 326-34. https://doi.org/10.1093/jnci/djj069
- Chaft JE, Oxnard GR, Sima CS, et al (2011). Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design. Clin Cancer Res, 17, 6298-303. https://doi.org/10.1158/1078-0432.CCR-11-1468
- Chen HJ, Yan HH, Yang JJ, et al (2013). Disease flare after egfr tyrosine kinase inhibitor cessation predicts poor survival in patients with non-small cell lung cancer. Pathol Oncol Res, 19, 833-8. https://doi.org/10.1007/s12253-013-9651-z
- Cheng Al, Kang YK, Chen Z, et al (2009). Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol, 10, 25-34. https://doi.org/10.1016/S1470-2045(08)70285-7
- Chung YH, Han G, Yoon JH, et al (2013). Interim analysis of START: Study in Asia of the combination of TACE (transcatheter arterial chemoembolization). with sorafenib in patients with hepatocellular carcinoma trial. Int J Cancer, 132, 2448-58. https://doi.org/10.1002/ijc.27925
- Dufour JF, Hoppe H, Heim MH, et al (2010). Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I study. Oncologist, 15, 1198-204. https://doi.org/10.1634/theoncologist.2010-0180
- Eisenhauer EA, Therasse P, Bogaerts J, et al (2009). New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer, 45, 228-47. https://doi.org/10.1016/j.ejca.2008.10.026
- El-Serag HB, Rudolph Kl (2007). Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology, 132, 2557-76. https://doi.org/10.1053/j.gastro.2007.04.061
- Gedaly R, Angulo P, Hundley J, et al (2010). PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways. Anticancer Res, 30, 4951-8.
- Huynh H, Ngo VC, Koong HN, et al (2009). Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma. J Cell Mol Med, 13, 2673-83. https://doi.org/10.1111/j.1582-4934.2009.00692.x
- Huynh H, Nguyen TT, Chow KH, et al (2003). Over-expression of the mitogen-activated protein kinase (MAPK). kinase (MEK)-MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis. BMC Gastroenterol, 3, 19. https://doi.org/10.1186/1471-230X-3-19
- Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90. https://doi.org/10.3322/caac.20107
- Llovet JM, Bru C, Bruix J (1999). Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis, 19, 329-38. https://doi.org/10.1055/s-2007-1007122
- Llovet JM, Ricci S, Mazzaferro V, et al (2008). Sorafenib in Advanced Hepatocellular Carcinoma. N Engl J Med, 359, 378-90. https://doi.org/10.1056/NEJMoa0708857
- Miyahara K, Nouso K, Morimoto Y, et al (2013). Efficacy of sorafenib beyond first progression in patients with metastatic hepatocellular carcinoma. Hepatol Res, 44, 296-301
- Park JW, Koh YH, Kim HB, et al (2012). Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma. J Hepatol, 56, 1336-42. https://doi.org/10.1016/j.jhep.2012.01.006
- Pinter M, Sieghart W, Graziadei I, et al (2009). Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis. Oncologist, 14, 70-6. https://doi.org/10.1634/theoncologist.2008-0191
- Pop O, Pirvu A, Toffart AC, Moro-Sibilot D (2012). Disease flare after treatment discontinuation in a patient with EML4-ALK lung cancer and acquired resistance to crizotinib. J Thorac Oncol, 7, 1-2. https://doi.org/10.1097/JTO.0b013e31823d4543
- Stock P, Monga D, Tan X, et al (2007). Platelet-derived growth factor receptor-alpha: a novel therapeutic target in human hepatocellular cancer. Mol Cancer Ther, 6, 1932-41.
- Strumberg D (2005). Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment. Drugs Today, 41, 773-84. https://doi.org/10.1358/dot.2005.41.12.937959
- Wang Z, Wu Xl, Zeng WZ, et al (2013). Meta-analysis of the efficacy of sorafenib for hepatocellular carcinoma. Asian Pac J Cancer Prev, 14, 691-4. https://doi.org/10.7314/APJCP.2013.14.2.691
- Wilhelm S, Carter C, Lynch M, et al (2006). Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov, 5, 835-44. https://doi.org/10.1038/nrd2130
- Worns MA, Weinmann A, Pfingst K, et al (2009). Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis. J Clin Gastroenterol, 43, 489-95. https://doi.org/10.1097/MCG.0b013e31818ddfc6
- Yang JJ, Chen HJ, Yan HH, et al (2013). Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer. Lung Cancer, 79, 33-9. https://doi.org/10.1016/j.lungcan.2012.09.016
- Yau T, Chan P, NG KK, et al (2009). Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response. Cancer, 115, 428-36. https://doi.org/10.1002/cncr.24029
피인용 문헌
- Survival of Hepatocellular Carcinoma Patients Treated with Sorafenib beyond Progression vol.5, pp.1-2, 2018, https://doi.org/10.1159/000487635